# Wave 2 director closure controller

Work only in your existing linked worktree. Never modify `.claude/**`, canonical
main, lane memos, cross-review files, numbered deliverables, or cached/fulltext
material. Read canonical inputs with `git show main:<path>`.

Use live `ListAgents` and `SendMessage` with the original uniquely named role
sessions. Do not launch or clone sessions. Route concise challenges and record
the role's actual reply. If a stopped role cannot reply, record the evidence-backed
resolution as director adjudication and leave a clear provenance note.

Write only:

`research/semaglutide_ckd_flow/2026-09-05/orchestration/WAVE2_DIALOGUE_LOG.md`

For every item record `CHALLENGE_SENT`, `RESPONSE_RECEIVED` (or explicitly
`NO_LIVE_RESPONSE_ROLE_STOPPED`), and one of `CLOSED_RESOLVED`,
`CLOSED_QUALIFIED`, or `CLOSED_OPEN_FOR_WAVE3`. Include accepted wording,
rejected wording, evidence locator, owner, and timestamp. Cover at minimum:

- `TN-001`: distinguish AE-driven permanent discontinuation 233/211,
  GI-specific 79/20, and overall any-reason discontinuation (primary report
  pooled 26% versus SGLT2 paper 28.8%, unresolved definitions).
- `NT-001`: reject 37.2%, 41.2%, 39.4%, and “35–40%” as exact CV-death shares.
  FLOW component counts overlap and are not a mutually exclusive first-event
  partition. Use only the source's approximate “about 35% of primary endpoint
  components”; exact first-event share is not derivable from aggregate counts,
  and this is never 35% of treatment effect. Ask trialist to acknowledge.
- `NT-002`: comparator-trial numbers remain unfit for final comparison unless
  checked against primary CREDENCE/DAPA-CKD/EMPA-KIDNEY/FIDELIO/FIDELITY
  publications; otherwise mark contextual/NR.
- `NT-003`: early stopping may have limited late hard-kidney component maturity,
  but differential impact is a hypothesis, not a demonstrated result.
- `MC-001`: subgroup/model consistency is not randomized additivity; no direct
  semaglutide+finerenone or triple/quadruple hard-outcome proof.
- `MC-002`: HbA1c-at-goal positioning requires organ-outcome RCT evidence plus
  independently verified guidance such as an “irrespective of A1C” recommendation;
  the FLOW HbA1c eligibility ceiling does not establish this.
- `CE-001`: distinguish Mahaffey EHJ 2025, Tuttle CJASN 2026 PMID 41706532,
  and Tuttle JACC 2026 PMID 42233552.
- `CE-002`: Neuen 2024 is a model based on separate class-level trials, not a
  semaglutide-specific or randomized combination study.

Also create placeholder sections `EC-*` and `LA-*` marked pending until the
endo-to-CKM review and librarian audit arrive. Do not claim Wave 2 is fully
closed while either file is absent.

Do not decide whether local NEJM files may be redistributed. Record: local
access basis unconfirmed; all-rights-reserved/personal-use material remains
private; no cloud parsing; claims must be independently verified from lawful
sources and short quotations only.

Commit this one file to your worktree branch and report the commit hash. Do not
push.
